Podcasts about ons

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

PSV moet winterbanden voor de platte kar bestellen, Van Persie vindt deze Klassieker geen topwedstrijd, en het lijkt of Grimsalabim kan toveren. Verder was AZ dit weekend met Herrie en Berrie op wereldreis, miste Heerenveen deze week drie Luuk Brouwers en bestormt El Karouani de Narsingh-index. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ik kwam binnen in het appartement van mijn gast, hoog in een toren in het centrum van Antwerpen, een indrukwekkend uitzicht over de hele stad. Ik was thuis bij voedingswetenschapper Michaël Sels (1989). Hij is diëtist met een specialisatie als oncologisch-diëtist. Hij werkt voor het UZA, het Universitair Ziekenhuis Antwerpen. Daar was hij jarenlang hoofddiëtist en is hij innovatiemanager klinische voeding. Hij schreef verschillende boeken met recepten, waaronder Lekker Lang Leven 1 en 2.We gingen in de woonkamer aan tafel zitten. Hij vertelt in ons gesprek waar hij soms boeken achterlaat als hij ze uitgelezen heeft. Ik vraag hem over zijn job als wetenschapper en diëtist in het ziekenhuis, over eten maken voor kankerpatiënten. Ons gesprek gaat over dieettips, over praten over homoseksualiteit, over het moment dat hij een concentratiekamp bezocht, over De zesde vijs, dat is een prijs die hij gekregen heeft.Wil je het boek '103 boeken die je gelezen moet hebben' bestellen - het boek van de podcast? Dat kan op ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.be.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ik schrijf er met plezier iets in voor jou of voor de persoon aan wie je het boek cadeau wil doen.Alle boeken en auteurs uit deze aflevering vind je⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠in de shownotes op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de nieuwsbrief in je mailbox? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.substack.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de podcast steunen? Bestel je boeken dan steeds via⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠de ⁠⁠link op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!⁠⁠ Merci.De drie boeken van Michaël Sels zijn:1. ⁠⁠⁠⁠⁠⁠⁠⁠⁠Tim 'S Jongers: Beledigende broccoli2. Koen Aelterman: Maak je geen zorgen over ons3. Heather Morris: De tatoeëerder van AuschwitzLuister ook naar de drie boeken van: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Eva Mouton⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Nicci French⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Josse De Pauw⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ish Ait Hamou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Murielle Scherre⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Michèle Cuvelier⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stefan Hertmans⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Françoise Chombar⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠en ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠vele anderen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Bezoek de productwijzer op https://productwijzer.justenough.nl/ Media, politiek, onderwijs: overal wordt hetzelfde dominante economische verhaal verteld. Maar wat als dat eenzijdige verhaal geen passend oplossingen heeft voor de problemen van deze tijd? Hoe maak je andere vormen van economisch denken bespreekbaar? Inzichtelijk? Hoe ga je de strijd aan met de status quo. Hoogleraar out-of-the-box-economics Irene van Staveren weet het. En doet het.In deze inspirerende podcast deelt ze economische inzichten die je bijna nooit hoort, maar tegelijkertijd onmisbaar zijn.Denk aan de financiële crises van 2007/2008. Wijlen de Engelse koningin Elizabeth ging vlak na het ontstaan van de financiële crises in 2007/2008 op bezoek bij het gerenommeerde London School of Economics en vroeg aan topeconomen hoe het toch mogelijk was dat niemand deze crisis zag aankomen? Waarom niemand hiervoor had gewaarschuwd? De economen kwamen niet verder dan een antwoord waarin ze stelden dan de crises veroorzaakt zijn door een schok. En een schok komt van buiten de economie en was daarmee voor hen niet te voorzien geweest. De rol van greed (hebzucht) werd in deze modellen niet meegenomen. Het is een veelzeggende illustratie van een van de blinde vlekken die aanwezig zijn in het hedendaagse dominante economische denken. Hoogleraar out-of-the-box-economics Irene van Staveren legt in deze podcast uit hoe zij tracht onze ogen hiervoor te openen. Of denk aan het mensbeeld van de homo economicus. Stel je loopt op een drukke straat, er rijden veel auto's en je ziet iemand voor je struikelen. Zonder erover na te denken, intuïtief, sleur je diegene voor de auto's vandaan. Volgens economen zouden we dat doen omdat we daarvoor een beloning verwachten. Ons handelen zou daarmee een calculerend handelen in plaats van intuïtief medemenselijk handelen zijn. Immers: al ons handelen komt volgens de heersende economische doctrine voort uit eigenbelang.Het is slechts één voorbeeld van verschillende dogma's in het hedendaagse dominante economische denken die getuigen van een smal economisch maatschappelijk- en mensbeeld. Dit is niet altijd zo geweest. En hoeft ook niet zo te blijven als het aan Irene van Staveren ligt. In deze podcast legt ze uit hoe zij de strijd aan gaat met de status quo in het land der economen.

Waldemar is zeer bekend als succesvol auteur, maar is ook opgevoed door hippie ouders, onder andere op de toen startende Warmonderhof en, via de documentaireserie Ondersteboven van... , diep betrokken geraakt bij de wijsheid van inheemse bevolkingen en hun relatie tot de aarde. Eerst in Afrika en daarna in de Amerika's.Ons gesprek is filosofisch, grappig, zelden praktisch, diepgaand, maatschappelijk betrokken, ecologisch, economisch en uiteindeljk ook heel persoonlijk. Hoe breek je af, en hoe stap je vervolgens een veel ecologischer werkelijkheid in?Meer informatie:Ondersteboven van AfrikaOndersteboven van de Amerika'sWikipedia

Send us a textJohannes 15:20-21 Onthou wat Ek vir julle gesê het: 'n Slaaf is nie belangriker as sy eienaar nie. As hulle My vervolg het, sal hulle julle ook vervolg. As hulle my woorde ter harte geneem het, sal hulle julle s'n ook ter harte neem. Maar hulle sal dit alles aan julle doen omdat julle my Naam bely en hulle Hom nie ken wat My gestuur het nie. Verwerping is een van die pynlikste dinge wat ons ooit kan deurmaak, want ons is gemaak om liefgehê en gekoester te word. Ons is sosiale wesens wat gemaak is om deel te wees van 'n gesin; ‘n familie; deel van 'n gemeenskap. Ja, verwerping kan verwoestend wees, maar dit is nie die einde nie. Verwerping hoef ons nie te definieer nie. Dit hoef ons nie te keer om ‘n vervullende lewe te lei nie.Harriet Tubman is in 1822 in Dorchester County, Maryland in die VSA gebore. Sy is as leier deur die samelewing verwerp. Hulle het haar geminag oor haar ras, en ook die feit dat sy ‘n vrou is.Nadat sy uit Maryland ontsnap het, het sy keer op keer teruggekeer om meer as sewentig mense wat gevange was, via die smokkelroete, bekend as die "Ondergrondse Spoorweg," te red. Sy het haar lewe gewaag en dertien keer teruggekeer, deur geheime roetes en veilige huise in Pennsilvanië en Kanada te gebruik.Haar moed en geloof het vir Harriet 'n blywende simbool van vryheid gemaak. Sy inspireer steeds vandag bewegings vir geregtigheid. Jesus het verwerping só aan sy dissipels verduidelik:Johannes 15:20-21 Onthou wat Ek vir julle gesê het: 'n Slaaf is nie belangriker as sy eienaar nie. As hulle My vervolg het, sal hulle julle ook vervolg. As hulle my woorde ter harte geneem het, sal hulle julle s'n ook ter harte neem. Maar hulle sal dit alles aan julle doen omdat julle my Naam bely en hulle Hom nie ken wat My gestuur het nie.Mense sal julle verwerp omdat julle in Jesus glo; omdat julle weier om deel te neem aan die boosheid van hierdie wêreld; omdat julle liefde betoon te midde van haat. Hulle het dit aan Jesus gedoen, hulle sal dit ook aan julle doen.Volg Jesus in elk geval. Leef ten spyte van verwerping ‘n betekenisvolle lewe.Dis God se Woord. Vars … vir jou … vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

Er worden alsmaar minder baby’s geboren in Europa, ook in ons land. Volgens sommigen eigenlijk angstwekkend weinig. We zijn ook niet de enigen. Van Italië over Rusland tot in China: overal stevenen we af op een razendsnelle bevolkingsafname. Een demografische crisis, vrezen bepaalde experts. Hoe komt het dat we niet genoeg kinderen meer willen maken? Hoe ontwrichtend kan die steile bevolkingsafname worden? En wat kunnen we daar eventueel aan doen? In deze Extra-aflevering van De 7 praten host Roan Van Eyck en journaliste Stephanie De Smedt met experts, burgemeesters en leden van de zes generaties die op dit moment in leven zijn. Over wat een kind vandaag exact kost, hoeveel geld ouders méér bijdragen aan de welvaartsstaat dan niet-ouders, en wat de dalende geboortecijfers nog betekenen voor onze economie. Lees: Wat de politiek ook probeert, ze zet er ons niet toe aan meer baby’s te maken Ons hele Gen6-dossier See omnystudio.com/listener for privacy information.

Ons is deel van die liggaam van Christus

Waarom weten we dit niet? Een extra lange en speciale aflevering over hormonen. Met host Sietske Atsma en co-host Maria Kooistra. Te gast zijn huisarts Lotte van Dijk en cosmetisch arts KNMG Charissa Geluk.Over Pamela Anderson, vaginale oestrogeengel op je gezicht smeren, de misvattingen over hormoonsuppletie en de zoektocht naar de juiste zorg.(00:00) intro(01:33) nieuws aan tafel(11:51) interview cosmetisch arts Charissa Geluk(27:42) hoofdonderwerp(01:09:20) outroShownotes:De wiemooiwilzijn podcast is er voor consumenten die een cosmetische ingreep overwegen en mensen die zich interesseren voor het maatschappelijke aspect van zelfverfraaiing.Ons doel is bij te dragen aan het maken van een juiste keuze. Wat de juiste keuze is, laten we aan de luisteraar. Een goed geïnformeerde consument is in staat dat voor zichzelf te bepalen.Sponsor: IBSA DermaHost: Sietske AtsmaAudio: Mustafa Al UbaidiStudio: 98cHeb je naar aanleiding van deze aflevering een vraag of heb je een suggestie voor de podcast? Reageer hier of neem contact met ons op via de website. Volg ons ook op Instagram!#hormonen #perimenopauze #menopauze #schoonheid #profhilo

Welkom bij een nieuwe aflevering van Groots! In deze aflevering, deelt Ciska van Grootveld haar persoonlijke ervaringen en inzichten over het creëren van een stevige basis voor groei – zowel praktisch als mentaal. Ons zenuwstelsel heeft een enorme invloed op het manifesteren van doelen, en je leert waarom ontspanning en een gevoel van veiligheid onmisbaar zijn voor echte vooruitgang. Ciska van Grootveld vertelt open over haar eigen struggles en overwinningen, en geeft je tips om je lichaam en brein in de ontvangmodus te krijgen. Of je nu grote ambities hebt of gewoon wat meer rust wilt in je leven, deze aflevering inspireert je om bewust te kijken naar wat groei voor jou betekent – en hoe je daarvoor de juiste omstandigheden creëert. Veel luisterplezier!

Sybrand Buma presenteerde zijn eindverslag. De volgende informateur staat alweer te trappelen. En woensdag debatteert de Tweede Kamer erover. Ons politieke duo volgt het op de voet: politiek duider Peter Kee (BNNVARA) en opiniemaker en eindredacteur Francisco van Jole (Joop.nl).

Ons volledige podcastaanbod vind je in Luister, in de app van De Standaard. Maar je kan als abonnee nu ook onze exclusieve reeksen, zoals Wat nu, Israël?, beluisteren op Spotify. Bij de afleveringen zie je een slotje staan. Als abonnee krijg je toegang door je abonnement op De Standaard (of een andere Mediahuistitel) te koppelen aan je Spotify-account. Klik op het slotje en volg de aangegeven stappen. Enkele kliks verder kan je al luisteren, ook als je geen betalend abonnement hebt bij Spotify. Wil je luisteren en ben je nog geen abonnee? Jongeren onder de 26 trakteren we nog tot eind dit jaar op een abonnement. Ben je ouder dan 26, dan lees én luister je al vanaf 3,15 euro per week. Ga daarvoor naar standaard.be/abonnement.See omnystudio.com/listener for privacy information.

Die ANC se geld- en ledetal-krisis onder die vergrootglas. 'n Ooreenkoms tussen Eskom en chroomsmelters kan die aflegging van duisende werkers stuit. Hoe gemaak wanneer jy by 'n padblokkade gedwing word om 'n boete te betaal? Ons praat met 'n regsgeleerde.

Send us a textJesaja 53:3 Hy was verag en deur die mense verstoot, 'n man van lyding wat pyn geken het, iemand vir wie die mense die gesig wegdraai. Hy was verag, ons het hom nie gereken nie. Dis snaaks hoe ons in hierdie moderne wêreld soveel dinge as noodsaaklik beskou. Dinge soos ‘n goeie regering, 'n eerlike regbank, koue en warm lopende water en natuurlik elektrisiteit. Ja, as jy gewoond is daaraan om dit dag na dag te hê, aanvaar jy dit ongetwyfeld as vanselfsprekend ... totdat dit skielik nie meer daar is nie.Neem byvoorbeeld elektrisiteit. Ons kan ons lewens skaars sonder elektrisiteit voorstel, nè? Ons weet hoe ons voel wanneer die krag skielik afgaan, net wanneer ons moet regmaak om iets belangrik te doen. Wie van ons het nie al beleef hoe ons skielik in die donker onder-in die kas na kerse moet grawe nie?Nikola Tesla is in 1856 in die hedendaagse Kroasië gebore. Hy is in 1943 oorlede. Die arme man het nie tydens sy leeftyd die erkenning vir sy ongelooflike werk ontvang nie. Hy is selfs afgedank en verneder.Ten spyte van armoede en openbare minagting het Tesla se werk met elektrisiteit – veral wisselstroom (WS) – die wêreld verander. Ons moet hom bedank vir die krag wat ons lewens verlig.Wanneer jy die een is wat bespot en ontslaan word, is dit nie 'n aangename ding nie. Dit voel verskriklik; asof jy nooit iets sal bereik nie; asof die lewe waarop jy gehoop het, nooit sal uitwerk nie.Jesaja het hierdie woorde oor Jesus meer as 700 jaar voor sy geboorte geskryf:Jesaja 53:3 Hy was verag en deur die mense verstoot, 'n man van lyding wat pyn geken het, iemand vir wie die mense die gesig wegdraai. Hy was verag, ons het hom nie gereken nie.En dit is presies wat met Hom gebeur het. Jesus se dood en opstanding sal altyd die grootste oorwinning in die menslike geskiedenis bly. Daardeur is mense vergewe en die gawe van die ewige lewe gegee.Net omdat sommige mense jou waarde nie raaksien nie, beteken nie dat God nie wonderlike dinge deur jou sal doen nie. Moenie bang wees vir die wêreld se verwerping nie.Dis God se Woord. Vars ... vir jou ... vandag. Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

PSV schaatst langs Heerenveen, Ueda scoort een head-trick en Ajax blijft maar winnen in 2026. Verder verliest AZ niet alleen punten maar ook een mascotte, pakt een niet gediplomeerde trainer een trainersprijs en staat Utrecht altijd waar het hoort als Vincent bij ons langskomt. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ons eindig 'n jaar van fassinerende boekpraatjies op Pagecast met 'n opwindende gesprek tussen Deon Meyer en Beer Adriaanse oor die topverkoper Skorpio. Bennie Griessel en Vaughn Cupido ontvang die blye tyding dat hulle uiteindelik weer bevorder is tot die rang van kaptein. Maar hul vreugde is van korte duur. Die vergruisde liggaam van een van Cupido se beste vriende is gevind onder die motor waaraan hy in sy motorhuis gewerk het... was dit 'n ongeluk, of koelbloedige moord? En op 'n imposante plaas buite Stellenbosch ontplof 'n woonwa. Onverklaarbaar. Nadat die vuur geblus is, word 'n liggaam in die wrak gevind... #DeonMeyer #BennieGriessel

Ons land telt meer langdurig zieken dan ooit. En achter die cijfers schuilen verhalen van mensen die, na ziekte of burn-out, opnieuw aansluiting zoeken bij werk en betekenis. Hun traject is zelden rechtlijnig. Het is een pad vol bochten en drempels. Recent onderzoek van de SERV (dat is De Sociaal-Economische Raad van Vlaanderen) zoomt in op dat pad. En het toont hoe relaties, maatwerk en mensgericht leiderschap het verschil maken. Niet regels of procedures bepalen of iemand duurzaam kan terugkeren naar werk, maar de kwaliteit van de relaties tussen werknemer, leidinggevende en omgeving. Duurzame re-integratie vraagt tijd, vertrouwen en menselijkheid. Vijf sleutels blijken daarbij bepalend. Wie daarop inzet, bouwt niet alleen aan herstel, maar ook aan veerkrachtige organisaties. Dat is de insteek van deze aflevering van #ZigZagHR Brainpickings, en bij mij zit Katrijn Vanderweyden van de SERV. Veel kijk- en luisterplezier!DOWNLOAD HET RAPPORT: https://www.serv.be/sites/default/files/documenten/SERV_STIA_20251006_Terugkeer_naar_werk_RAP.pdf LEES HET ARTIKEL: https://zigzaghr.be/terug-naar-werk-na-ziekte-vijf-sleutels-voor-duurzame-re-integratie/Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF BLIJF OP DE HOOGTE VAN ALLE HR-ACTUA ABONNEER JE OP HET #ZIGZAGHR BOOKAZINE It's a great time to be in HR! www.zigzaghr.be

Tim van Rijthoven blikt terug op zijn tenniscarrière, die hij in 2025 voortijdig beëindigde wegens een slepende elleboogblessure. Wat heeft de tennissport hem gebracht én gekost? En hoe zwaar was het om de knoop om te stoppen definitief door te hakken? De NL Tennis Podcast wordt gepresenteerd door Marcella Mesker en Jan-Willem de Lange. De titelmuziek is van Anthony Vega. De NL Tennis Podcast wordt onder meer verspreid via de nieuwsbrief van PassaTennis. De coverfoto is geleverd door Tennis Images. Reageren op deze podcast? Je vindt ons op X: @NLTennisPodcast. Instagram: @nltennispodcast. Ons mailadres is nltennispodcast@gmail.com.

Ons praat met 'n politieke ontleder oor die ANC se hoofraadsvergadering. Dis nog onseker of die sluipmoord op Marius van der Merwe weens sy getuinis voor die Madlanga-kommissie was, of sy stryd teen onwettige mynboubedrywighede. Kommer oor gerugte dat die verspreiding van bek-en-klouseer-inentings gesaboteur word.

Ons gemeenskap deel soveel met mekaar en tog kies ons keer op keer om te baklei in plaas van te bou.

Send us a textHandelinge 3:19,20 Daarom, bekeer julle en kom tot inkeer. Dan sal God julle sondes uitwis. En dan sal daar tye van verkwikking van die Here af kom en sal Hy Jesus stuur, wat vooraf vir julle as die Christus aangewys is. Om ‘n byna perfekte lewe te leef, is nie maklik nie. As dit was, sou almal dit gedoen het. Maar ons weet niemand slaag daarin nie. Ja, wel, soms besluit ons om hierdie slegte ou gewoontetjie te laat vaar, of met daardie goeie een te begin, maar uiteindelik word dit alles net te moeilik, en ons gly lag-lag terug in ons ou patroon.Ons was almal al in daardie situasie, of hoe? Met goeie voornemens is dit moeilik genoeg om 'n verandering van gewoonte aan te kweek, maar amper onmoontlik om daarmee vol te hou.Daar is baie mense in hierdie wêreld wat ten minste al die idee om ‘n Christen te word, oorweeg het. Maar dis moeilik. Die meeste ouens is tevrede met 'n afgewaterde: Ja, seker ek glo in God. Maar, my vriend, dit het hul lewens nie in die minste verander nie; dit het hulle nie nader aan die perfekte, gelukkige lewe, wat hulle gehoop het hulle nou sou hê, gebring nie. Die werklikheid lyk anders:Handelinge 3:19,20 Daarom, bekeer julle en kom tot inkeer. Dan sal God julle sondes uitwis. En dan sal daar tye van verkwikking van die Here af kom en sal Hy Jesus stuur, wat vooraf vir julle as die Christus aangewys is.Ja, natuurlik begeer ons daardie verkwikking wat kom deur naby aan God te wees. Ons wil dit hê! Maar ons is te papbroekerig om weg te draai van dít wat ons weet verkeerd is; en om terug te keer na God, voordat ons daardie verkwikking sal ervaar.Ons is bereid om tot inkeer te kom sodat ons vergewe kan word - maar is ons bereid om verander te word, om weg te draai van die sonde waaraan ons vasklou, om die verkwikking waarna ons so verlang, vas te gryp en om ‘n lewe tot eer van God te lei?Wel, is jy?Daarom, bekeer julle en kom tot inkeer. Dan sal God julle sondes uitwis. En dan sal daar tye van verkwikking van die Here af kom en sal Hy Jesus stuur, wat vooraf vir julle as die Christus aangewys is. Dis Sy Woord. Vars ... vir jou ... vandag.Support the showEnjoying The Content?For the price of a cup of coffee each month, you can enable Christianityworks to reach 10,000+ people with a message about the love of Jesus!DONATE R50 MONTHLY

‘Ons hart was sterk. God laat ons niet in de steek.'

"Als het systeem je kind niet ziet", afl 313 In deze aflevering ga ik in gesprek met Karin Zwennicker, moeder van een inmiddels volwassen dochter met een LVB én jeugdprofessional. We praten over wat het betekent om moeder te zijn van een kind dat niet 'gewoon mee kan doen', en hoe zij aankijkt tegen het systeem van onderwijs en zorg. De volgende aflevering praat ik verder met Karin over haar professionele visie. Maar eerst: als moeder!   Karin vertelt hoe het is als je dochter niet past in de vakjes van school, zorg en beleid. En hoe snel je als ouder weggezet wordt als lastig, terwijl je wanhopig probeert voor je kind op te komen of haar te beschermen. Haar verhaal, hun verhaal, laat voelen hoe het systeem langs mensen heen kan kijken, en hoe pijnlijk het is als professionals handelen vanuit regels in plaats van relatie.     Ons gesprek raakt aan levend verlies, het steeds opnieuw moeten vechten en de eenzaamheid die ontstaat als je niet wordt geloofd. Maar ook aan veerkracht, de enorme liefde van een ouder voor haar kind en hoe één professional het verschil maakt door te luisteren.    Eigenlijk alle thema's van Professional vanuit je hart komen wel langs in dit gesprek, vanuit het perspectief van een ouder die wel 300 zorgverleners voorbij heeft zien komen.   Luister mee naar een verhaal dat onder je huid kruipt. Wat jij doet en hoe je het doet maakt álle verschil voor de mensen die zich in een kwetsbare positie bevinden.    De Professional vanuit je hart Podcast vind je op de meeste podcastapps, Spotify en YouTube. Leuk als je een reactie achterlaat!

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

Vandaag een gesprek dat wat losser begon en waarin van alles langkomt, maar uiteindelijk precies gaat over waarom het soms zo moeilijk is om écht te zeggen wat je voelt… Stel: je zit samen op de bank met je (nieuwe) partner. Alles lijkt goed. Maar vanbinnen voel je zoveel dat je zou willen zeggen. Je mist die diepe connectie, je wil je openstellen, écht delen wat er in je leeft. Maar zodra je je mond wilt openen, slaat de twijfel toe. Wat als ik het verkeerd zeg? Wat als ik te veel ben? Wat als hij wegloopt? Renske, 48 jaar, heeft een nieuwe relatie, met een groot verlangen om zich kwetsbaar te tonen, maar ook met een knoop in haar buik. Ze weet zelf ook: het is angst voor afwijzing. En toch lukt het niet om het patroon te doorbreken. In deze aflevering duiken David en Arjan in dit universele dilemma: waarom is het in de liefde soms zó moeilijk om echt te zeggen wat we voelen? Hoe ontstaat die angst? En belangrijker nog: hoe vind je de weg terug naar verbinding, met jezelf én met de ander?Een aflevering over overlevingsmechanismen, generaties aan stilte, de kracht van kwetsbaarheid en hoe je als geliefden de brug kunt bouwen tussen twee binnenwerelden.

Waar zal Europa het geld halen om Oekraïne in 2026 en 2027 structureel te helpen? Als het van 26 lidstaten afhangt: in België, waar minstens 140 miljard euro aan Russische tegoeden geblokkeerd zit. Ideaal voor een “herstellening” aan het getroffen land, meent de EU. Maar premier Bart De Wever houdt het been stijf. Want voor ons land zijn er té veel risico's aan verbonden, meent De Wever. Hij wil het geld pas vrijgeven als er waterdichte garanties komen. Met de Europese top van 18 december in zicht, moet de zaak nu echt wel landen. De politieke en geopolitieke druk op premier Bart De Wever (N-VA) is groot. Ons land staat alleen in zijn verzet tegen het “herstelplan” van de Europese commissievoorzitter Ursula von der Leyen. Komt De Wever hier als winnaar uit? Alles hangt af van de garanties die zullen worden beklonken, en van het akkoord van de 26 andere lidstaten, weet Europawatcher Bart Beirlant van onze buitenlandredactie. CREDITS Journalist Bart Beirlant | Presentatie en eindredactie Marjan Justaert | Redactie Alexander Lippeveld, Sofie Steenhaut | Audioproductie en muziek Brecht Plasschaert | Chef podcast Alexander Lippeveld See omnystudio.com/listener for privacy information.

Ons wagenpark moet steeds meer elektrisch worden, maar vandaag werd bekend dat Nederlanders juist steeds minder staan te trappelen om een elektrische auto te kopen. De reden? Zwalkend overheidsbeleid vooroordelen over elektrisch rijden. Het blijkt allemaal uit de Elektrisch Rijden Monitor van de ANWB. Zijn de vooroordelen terecht?  Een gesprek met Chiel van Lent, projectleider van de Elektrisch Rijden Monitor van de ANWB, en met Frank Jacobs, journalist bij Autoweek.

UnHerd's Freddie Sayers speaks with migration expert Dr. Madeleine Sumption to dissect the latest ONS figures which reveal a dramatic crash in UK net migration. Is this truly caused by an alarming "exodus of fed-up Brits," as some headlines suggest, or is the surge in people leaving the country, in fact, the long-overdue re-migration of earlier non-EU and EU immigrants—a data-driven truth that fundamentally upends how the media and public understand the entire politics of immigration? Hosted on Acast. See acast.com/privacy for more information.

Laura (50) is moeder van een samengesteld gezin met een puberende zoon (met autisme) die extra zorg vraagt. Liefdevol, maar intens. Haar dagen staan in het teken van zorgen, regelen en ‘voorkomen dat het misgaat'. Altijd alert. Alsof ontspanning geen optie meer was. Ze probeerde jarenlang verlichting te vinden in therapie, yoga, coaching en mindfulness. Maar de zwaarte bleef. Ze zegt erover: "Het voelde alsof ik stikte in mijn eigen leven." Totdat er iets veranderde. In dit open en eerlijke gesprek met Arjan vertelt Laura hoe ze langzaam leerde om minder te vechten en zachter te kijken — naar haar kinderen, het leven, maar vooral naar zichzelf. Over hoe het voelde om echt gezien te worden in een groep. En hoe het is om eindelijk niet meer alles alleen te hoeven doen. Het is een aflevering voor iedereen die zich weleens afvraagt: is dit het nou? En verlangt naar meer ademruimte, verbinding en innerlijke rust. Luister nu — en ontdek wat er mogelijk wordt als je stopt met overleven.Let op: wil je deelnemen aan Miracle Roadmap in februari 2026, de inschrijving is nú open en inschrijven kan t/m 10 december. Regel het hier HIER met korting. Wil je even met ons appen om jouw situatie te bespreken? Dat kan via 06-21997689.Shownotes:Leuk als je reageert op de podcast onder deze aflevering in de comments, via youtube, of via onze socials.Heb je zelf een vraag of een tip?❓ Stuur het hier!Onze programma's:✨ Miracle Roadmap

Inwoners van woonbuurte soos Westbury, Newclare en Bosmont in Gauteng betoog teen bendegeweld. Die parlement, op aandrang van die EFF, gaan 'n ondersoek na bendegeweld in Kaapstad begin. Ons praat oor kommunikasie tussen mense wat verskillende tale praat.

PSV wint de Veerman-derby, Robin van Persie heeft 25 zoons en Ajax blijft ongeslagen door buiten het veld te verliezen. Verder probeerde Troy Ihattaren na-te-papegaaien, trekken de Eagles deze keer een sportieve lange neus en blijft Krüzen als enige Heracles-trainer ooit ongeslagen. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft, deze week met SJOERD MOSSOU! ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

Ons is vandag op die sewende dag van die 16 Dae van Aktivisme teen vrouegeweld. Intussen is twee vroue vermoor, twee verkrag en een kind verwaarloos. Kosmos 94.1 Nuus het met maatskaplike aktivis en direkteur van Civic +264, Ethne Mudge, gepraat. Sy meen dit is van kritieke belang om seuns en mans by die veldtog te betrek.

Helena de Groot (1983) woont in New York, waar ze werkt als podcastmaker voor The Poetry Foundation en voor The Paris Review. Ze werkt ook aan een eigen podcast over haar beslissing om geen kinderen te krijgen: Creation Myth.Ons gesprek vond plaats bij mij thuis en is erg emotioneel. Het gaat over aandacht, over menselijkheid, en over leven in New York. Over de abortuskliniek waar ze enkele jaren geleden kwam. En ze vertelt hoe Salman Rushdie een brief kwam inspreken voor één van de literaire podcasts waarvoor ze werkt.Wil je het boek '103 boeken die je gelezen moet hebben' bestellen - het boek van de podcast? Dat kan op ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.be.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ik schrijf er met plezier iets in voor jou of voor de persoon aan wie je het boek cadeau wil doen.Alle boeken en auteurs uit deze aflevering vind je⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠in de shownotes op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de nieuwsbrief in je mailbox? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠wimoosterlinck.substack.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wil je de podcast steunen? Bestel je boeken dan steeds via⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠de ⁠⁠link op wimoosterlinck.be⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!⁠⁠ Merci.De drie boeken van Helena de Groot  zijn:1. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Roald Dahl: Matilda2. Svetlana Alexijevitsj: Het einde van de rode mens3. Nicholson Baker: The MezzanineLuister ook naar de drie boeken van: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Eva Mouton⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Nicci French⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Josse De Pauw⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ish Ait Hamou⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Murielle Scherre⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Michèle Cuvelier⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stefan Hertmans⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Françoise Chombar⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠en ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠vele anderen⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Toen Esther 23 jaar geleden moeder werd, veranderde alles. Haar dagen vulden zich als vanzelf met zorgen, liefde, hectiek en betekenis. Maar nu, nu het huis stil is en de kamers leeg, blijft zij achter met een gevoel dat ze zelf niet had zien aankomen: een diepe, stille leegte. Haar kinderen zijn op kamers, hun vleugels uitgeslagen en hoewel ze trots is, voelt het alsof een deel van haar verdwenen is.Hoe geef je opnieuw betekenis aan je leven als je belangrijkste rol, moeder zijn, niet meer je dagelijkse werkelijkheid is? Wat doe je als het "lege nest" niet alleen stil is, maar ook zinloos voelt? In deze aflevering duiken David en Arjan in het rauwe en herkenbare gevoel van het "empty nest syndrome". Ze benoemen het voor wat het is: een rouwproces. Met warmte, humor en diepgang verkennen ze hoe je kunt omgaan met die leegte, welke valkuilen er zijn, en vooral: hoe je kunt groeien naar een nieuwe fase vol zingeving, liefde en richting — niet ondanks, maar dankzij dit gemis.Een aflevering voor iedereen die iets moet loslaten wat ooit het mooiste in hun leven was.Let op: wil je deelnemen aan Miracle Roadmap in februari 2026, de inschrijving is nú open en inschrijven kan t/m 10 december. Regel hier HIER met korting. Wil je even met ons appen om jouw situatie te bespreken? Dat kan via 06-21997689.Shownotes:Leuk als je reageert op de podcast onder deze aflevering in de comments, via youtube, of via onze socials.Heb je zelf een vraag of een tip?❓ Stuur het hier!Onze programma's:✨ Miracle Roadmap

Healing is an important piece of rehabilitating trauma. Without healing it can be hard for people to move forward with life and on to healthier behaviors. Today we talk with Dr. Darlene Fry from the IGF Black Youth Healing Arts Center and discover the many different components of healing through the arts.  Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

Ons denken over seks is niet uit de lucht komen vallen. Of het nou gaat over het huwelijk, de positie van de vrouw en homoseksualiteit: de geschiedenis is complex en beladen. Maar altijd fascinerend. Wat heeft onze seksuele moraal gevormd?  En wat als de seksuele revolutie niet pas begon in de jaren ‘60, maar in de eerste eeuw na Christus? Luister nu De Ongelooflijke Geschienis - met Beatrice de Graaf en Stefan Paas - in je favoriete podcast-app: Spotify (https://open.spotify.com/show/6wrZOzkWhTftj68h3GVgvq) Apple Podcasts (https://podcasts.apple.com/nl/podcast/de-ongelooflijke-geschiedenis/id1850467317) NPO Luister (https://npo.nl/luister/podcasts/1332-de-ongelooflijke-geschiedenis) Podimo (https://share.podimo.com/s/Us91QrpQ) En vergeet je niet abonneren zodat je ook de volgende afleveringen niet hoeft te missen.

Eindhovense storm zwakt af tot briesje, Feyenoord’s crisismeter begint uit te slaan en de crisismeter van Ajax is volledig opgeblazen. Verder trekt de schokeffect Guardiola de lijn door, hebben we te maken met de oudste-jongste debutant ooit en vieren we de terugkeer van de oranje bal in de Groen-Witte Kathedraal. Het is maandagavond op naar een nieuwe aflevering van De Derde Helft. ✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukIn this bonus episode, I spoke with Ed West about the new data indicating that British citizens are emigrating in much larger numbers than anyone realised. We also spoke about how emigration has shaped the Anglosphere and the proposed reforms to the asylum system. Discussed in the episode:* ONS revised emigration estimates – https://www.ons.gov.uk/peoplep…

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Morse code transcription: vvv vvv HP seeking 1.7bn from Mike Lynchs estate UK net migration dropped more than first reported, ONS says Sisters jealous ex lit fatal Bradford house fire, jury told How to stop your phone habit ruining your relationship Loose wire on ship may have led to Baltimore bridge collapse, report says Things happen Trump defends Saudi crown prince over Khashoggi killing Strictly Come Dancing La Voix devastated to miss Blackpool specials due to injury Palestine Action activist struck officer with sledgehammer, court hears Snow and ice warnings come into force across Scotland Line of Duty to return for seventh series, BBC confirms

Morse code transcription: vvv vvv Line of Duty to return for seventh series, BBC confirms Sisters jealous ex lit fatal Bradford house fire, jury told UK net migration dropped more than first reported, ONS says Palestine Action activist struck officer with sledgehammer, court hears Strictly Come Dancing La Voix devastated to miss Blackpool specials due to injury Loose wire on ship may have led to Baltimore bridge collapse, report says HP seeking 1.7bn from Mike Lynchs estate Snow and ice warnings come into force across Scotland How to stop your phone habit ruining your relationship Things happen Trump defends Saudi crown prince over Khashoggi killing

Morse code transcription: vvv vvv Line of Duty to return for seventh series, BBC confirms HP seeking 1.7bn from Mike Lynchs estate Strictly Come Dancing La Voix devastated to miss Blackpool specials due to injury How to stop your phone habit ruining your relationship Palestine Action activist struck officer with sledgehammer, court hears Snow and ice warnings come into force across Scotland UK net migration dropped more than first reported, ONS says Things happen Trump defends Saudi crown prince over Khashoggi killing Loose wire on ship may have led to Baltimore bridge collapse, report says Sisters jealous ex lit fatal Bradford house fire, jury told

Economics editor Michael Simmons and Yvette Cooper's former adviser Danny Shaw join Patrick Gibbons to react to the Home Secretary's plans for asylum reform. Shabana Mahmood's direct communication style in the Commons yesterday has been praised by government loyalists and right-wingers alike, but her plans have been criticised by figures on the left as apeing Reform. Will her calculated risk pay off and how will success be judged?Plus, as ONS migration figures are revised – again – Michael restates his appeal for more reliable data. And how could migration data affect the budget next week?Produced by Patrick Gibbons.Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcasts.Contact us: podcast@spectator.co.uk Hosted on Acast. See acast.com/privacy for more information.

Het Nederlands Elftal heeft zich, als je dit luistert, hopelijk geplaatst voor het WK, maar vanaf de roze wolk is de opvolging van Koeman nú al onderwerp van gesprek. Verder hoop iedereen op het (als we Dick een beetje inschatten) toch een-na-laatste kunstje van Advocaat en is Halfgod Troy Parrott is minstens tien keer zo goed als Mexx Meerdink. Welkom bij De Derde Helft. Ook dit seizoen zijn jullie nog niet van ons af. Integendeel. Je kunt ons meer, vaker, langer en op meer verschillende kanalen volgen (en wellicht bewonderen) dan ooit. In deze podcast hebben Snijboon, Tim en Pepijn het over alle zin en onzin rondom het interlandweekend.✉️ Op vrijdag kunnen jullie met ons via Substack vooruitblikken op het aankomende Eredivisie-weekend. Gijs, Tim, Snijboon, Pepijn en RogierPablo zullen hier allemaal één ding delen waar ze naar uitkijken in de aankomende speelronde. https://substack.com/@dederdehelft

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

ONS has done so many things to change the way we look at alternative public safety initiatives, and we've done it under the leadership of Director Blakey. Today we connect with Brooke Blakey as she removes her cape, retiring from her role at ONS. We are laughing, crying and looking back on the successes of the ONS office before she embarks on her new beginnings, and we move forward as an office. Check out more great episodes at f2fpodcastnetwork.comAlso, check the F2F Podcast Network on YouTube

In The People vs. the Golden State Killer, Thien Ho, the current District Attorney of Sacramento, recounts his harrowing and exhilarating experience as the lead prosecutor responsible for capturing and prosecuting Joseph DeAngelo. Referred to at various times by law enforcement and the media as the Visalia Ransacker, the East Bay Rapist, the Original Nightstalker, and finally the Golden State Killer, DeAngelo, a former policeman, is widely considered “one of the most notorious serial predators in American history.Ho's book is the first official account of how the Golden State Killer was apprehended and put behind bars for life. Ho led an elite team of law enforcement from six California prosecutor's offices, using a newly developed tool known as “investigative genetic genealogy” to connect DeAngelo to multiple cold cases stretching back nearly a half century.Many previous narratives about DeAngelo, including two bestselling books and multiple documentaries, focused largely on the killer and his heinous crimes. This book not only provides hundreds of facts and details never revealed to the public about the Golden State Killer's crimes, it also presents the real-life story of the people who worked tirelessly to bring DeAngelo to justice. It also offers the unprecedented authorized perspective of three survivors of DeAngelo's crimes who courageously turned their pain into empowerment and activism. A portion of the book's proceeds will be donated both by the author and Third State Books to Phyllis's Garden, a nonprofit advocating for victims' rights begun in honor of a GSK survivor.The People vs. the Golden State Killer also recounts Ho's fascinating personal journey, from escaping communist Vietnam with his family as a child to working his way up from an internship to an elite homicide division and eventually becoming one of only ten Asian American district attorneys out of 2,400 nationwide. THE PEOPLE vs THE GOLDEN STATE KILLER: Sacramento District Attorney—Thien Ho

"I think we really need to push more of our oncology nurses to get into elected and appointed positions. So often we're looking at health positions to get involved in, and those are wonderful. We need nurses as secretaries of health, but there are others. We as nurses understand higher education. We understand environment. We understand energy. So I think we look broadly at, what are positions we can get in? Let's have more nurses run for state legislative offices, for our House of Representatives, for the U.S. Senate," ONS member Barbara Damron, PhD, LHD, RN, FAAN, told Ryne Wilson, DNP, RN, OCN®, CNE, ONS member and member of the ONS 50th anniversary committee, during a conversation about the future of oncology nursing advocacy and health policy. Wilson spoke with Damron and ONS member Janice Phillips, PhD, RN, CENP, FADLN, FAAN, about how ONS has advanced advocacy and policy efforts over the past 50 years and its approaches for the future. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: ONS 50th anniversary series Episode 229: How Advocacy Can Shape Your Nursing Career ONS Voice articles: Oncology Nurses Take to Capitol Hill to Advocate for Cancer Care Priorities Our Unified Voices Can Improve Cancer Survivorship Care With Voices Amplified by ONS, Oncology Nurses Speak Out for Patients and the Profession on Capitol Hill NOBC Partnerships Advance Nurses' Placements on Local and National Boards Nursing Leadership Has Space for You and Your Goals ONS courses: Advocacy 101: Making a Difference Board Leadership: Nurses in Governance Oncology Nursing Forum articles: Nurses on Boards: My Experience on the Moonshot Strengthening Oncology Nursing by Using Research to Inform Politics and Policy ONS Center for Advocacy and Health Policy Current ONS position statements Connie Henke Yarbro Oncology Nursing History Center Campaign for Tobacco-Free Kids Cancer Moonshot National Cancer Policy Forum National Council of State Boards of Nursing APRN Roundtable National Patient Advocate Foundation Nurses on Boards Coalition One Voice Against Cancer Patient Quality of Life Coalition Robert Wood Johnson Foundation Health Policy Fellows To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Phillips: "I think that there are so many pressing issues, but I'm going to start with any kind of threats or legislation that's poised to take away safety-net resources. It's really going to set us back because we all know that, particularly for minorities and certain other underserved populations, they have experienced poor cancer outcomes for a variety of reasons, variety of socioeconomic reasons, lack of access to quality screening resources—you name it. When you take away those safety net resources and take away resources for people who are already underserved, uninsured, or underinsured, it also jeopardizes their ability to get proper screening, get proper follow-up, have access to state of the art cancer services. I think the lack of affordability of health care is a problem that continues to challenge us, whether you on Medicaid or whether you have limited insurance." TS 10:16 Damron: "Because ONS is so grounded in science and research—we're not just a clinical organization; we're grounded in scholarship, science, research, and publication—we're able to take this vast network of strong clinicians [and combine it] with amazing scientists. … We've had some amazing scientists come out of ONS; some of the leading nurse scientists of all time were also oncology nurses. So by combining this, we're able to make a difference at the state and federal level. So the advocacy work that I've been involved in, state and federal levels, really involved working with the ONS staff involved with advocacy and those scientists and clinicians who brought that expertise." TS 18:19 Phillips: "I think expanding the work around multiculturalism in oncology will always be important. Are there any new partnerships or avenues that ONS can reach out to or explore? Maybe there are other specialty organizations or groups—and not always necessarily nursing— because as we think about the determinants of health, we think about things like health and all policies. Maybe there are other disciplines or other specialties that we need to embrace as we launch our agendas." TS 23:28 Damron: "As nurses, just our basic nursing training, we get these skills—we see a problem, we identify the problem, we assess what we're going to do about it, we do it, and then we evaluate what we did. Does that work or not? That's how you make policy. So we were all trained in this. Then what you bring on top of that are oncology nursing experience, whether it's clinical, whether it's research, whether it's teaching, practice, etc. Those continue to refine those skills that are basic to us as nurses. We have this built-in skill set, and we need to own it and understand it." TS 30:25